Bibliography:
1. Wamboldt R, Haseeb S, Waddington A, Baranchuk A. Cardiac arrhythmias secondary to hormone therapy in trans women. Expert Rev Cardiovasc Ther [Internet]. 2019;17(5):335–43. Available from: https://doi.org/10.1080/14779072.2019.1606713
2. Sedlak T, Shufelt C, Iribarren C, Merz CNB. Sex hormones and the QT interval: A review. J Women’s Heal. 2012;21(9):933–41.
3. Abi-Gerges N, Philp K, Pollard C, Wakefield I, Hammond TG, Valentin JP. Sex differences in ventricular repolarization: From cardiac electrophysiology to Torsades de Pointes. Fundam Clin Pharmacol. 2004;18(2):139–51.
4. Kwong JCC, Krakowsky Y, Grober E. Testosterone Deficiency: A Review and Comparison of Current Guidelines. J Sex Med [Internet]. 2019;16(6):812–20. Available from: https://doi.org/10.1016/j.jsxm.2019.03.262
5. Kumar P, Kumar N, Thakur DS, Patidar A. Male hypogonadism: Symptoms and treatment. J Adv Pharm Technol Res. 2010;1(3):297–301.
6. Kloner RA, Carson C, Dobs A, Kopecky S, Mohler ER. Testosterone and Cardiovascular Disease. J Am Coll Cardiol. 2016;67(5):545–57.
7. Moher D, Liberati A, Tetzlaff J, Altman DG, Altman D, Antes G, et al. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med. 2009;6(7).
8. Schwartz JB, Volterrani M, Caminiti G, Marazzi G, Fini M, Rosano GMC, et al. Effects of testosterone on the Q-T Interval in older men and older women with chronic heart failure. Int J Androl. 2011;34(5 PART 2):415–21.
9. Zhang Y, Ouyang P, Post WS, Dalal D, Vaidya D, Blasco-Colmenares E, et al. Sex-steroid hormones and electrocardiographic qt-interval duration: Findings from the third national health and nutrition examination survey and the multi-ethnic study of atherosclerosis. Am J Epidemiol. 2011;174(4):403–11.
10. Hiremath PG, Bhondoekhan F, Haberlen SA, Ashikaga H, Palella FJ, D’Souza G, et al. Testosterone use and shorter electrocardiographic QT interval duration in men living with and without HIV. HIV Med. 2020;1–4.
11. Vicente J, Simlund J, Johannesen L, Sundh F, Florian J, Ugander M, et al. Investigation of potential mechanisms of sex differences in quinidine-induced torsade de pointes risk. J Electrocardiol [Internet]. 2015;48(4):533–8. Available from: http://dx.doi.org/10.1016/j.jelectrocard.2015.03.011
12. Barber M, Nguyen LS, Wassermann J, Spano JP, Funck-Brentano C, Salem JE. Cardiac arrhythmia considerations of hormone cancer therapies. Cardiovasc Res. 2019;115(5):878–94.
13. Haque R, Ulcickasyood M, Xu X, Cassidy-Bushrow AE, Tsai HT, Keating NL, et al. Cardiovascular disease risk and androgen deprivation therapy in patients with localised prostate cancer: A prospective cohort study. Br J Cancer [Internet]. 2017;117(8):1233–40. Available from: http://dx.doi.org/10.1038/bjc.2017.280
14. Lazzerini PE, Bertolozzi I, Acampa M, Cantara S, Castagna MG, Pieragnoli L, et al. Androgen Deprivation Therapy for Prostatic Cancer in Patients With Torsades de Pointes. Front Pharmacol. 2020;11(May):1–11.
15. Gheorghe ACD, Ciobanu A, Hodorogea AS, Radavoi GD, Jinga V, Nanea IT, et al. Evolution of Electrocardiographic Repolarization Parameters During Antiandrogen Therapy in Patients with Prostate Cancer and Hypogonadism. Cardiovasc Toxicol [Internet]. 2020;20(4):390–400. Available from: https://doi.org/10.1007/s12012-020-09566-6
16. Belderbos BPSI, de Wit R, Chien C, Mitselos A, Hellemans P, Jiao J, et al. An open-label, multicenter, phase Ib study investigating the effect of apalutamide on ventricular repolarization in men with castration-resistant prostate cancer. Cancer Chemother Pharmacol [Internet]. 2018;82(3):457–68. Available from: http://dx.doi.org/10.1007/s00280-018-3632-6
17. Salem JE, Bretagne M, Lebrun-Vignes B, Waintraub X, Gandjbakhch E, Hidden-Lucet F, et al. Clinical characterization of men with long QT syndrome and torsades de pointes associated with hypogonadism: A review and pharmacovigilance study. Arch Cardiovasc Dis [Internet]. 2019;112(11):699–712. Available from: https://doi.org/10.1016/j.acvd.2019.06.008
18. Grouthier V, Lebrun-Vignes B, Glazer AM, Touraine P, Funck-Brentano C, Pariente A, et al. Increased long QT and torsade de pointes reporting on tamoxifen compared with aromatase inhibitors. Heart. 2018;1–5.
19. Abehsira G, Bachelot A, Badilini F, Koehl L, Lebot M, Favet C, et al. Complex influence of gonadotropins and sex steroid hormones on QT interval duration. J Clin Endocrinol Metab. 2016;101(7):2776–84.
20. JØrgensen IN, SkakkebÆk A, Andersen NH, Pedersen LNø, Hougaard DM, Bojesen A, et al. Short QTc interval in males with klinefelter syndrome - Influence of CAG repeat length, body composition, and testosterone replacement therapy. PACE - Pacing Clin Electrophysiol. 2015;38(4):472–82.
21. Pecori Giraldi F, Toja PM, Filippini B, Michailidis J, Scacchi M, Stramba Badiale M, et al. Increased prevalence of prolonged QT interval in males with primary or secondary hypogonadism: A pilot study. Int J Androl. 2010;33(1).
22. Bidoggia H, Maciel JP, Capalozza N, Mosca S, Blaksley EJ, Valverde E, et al. Sex differences on the electrocardiographic pattern of cardiac repolarization: Possible role of testosterone. Am Heart J. 2000;140(4):678–83.
23. Giraldi FP, Manzoni G, Michailidis J, Scacchi M, Stramba-Badiale M, Cavagnini F. High prevalence of prolonged qt interval in obese hypogonadal males. Obesity [Internet]. 2011;19(10):2015–8. Available from: http://dx.doi.org/10.1038/oby.2011.33/nature06264
24. Charbit B, Christin-Maître S, Démolis JL, Soustre E, Young J, Funck-Brentano C. Effects of Testosterone on Ventricular Repolarization in Hypogonadic Men. Am J Cardiol [Internet]. 2009;103(6):887–90. Available from: http://dx.doi.org/10.1016/j.amjcard.2008.11.041
25. Adigun AQ, Pinto AG, Flockhart DA, Gorski JC, Li L, Hall SD, et al. Effect of cirrhosis and liver transplantation on the gender difference in QT interval. Am J Cardiol. 2005;95(5):691–4.
26. Vrtovec B, Meden-Vrtovec H, Jensterle M, Radovancevic B. Testosterone-related shortening of QTc interval in women with polycystic ovary syndrome. J Endocrinol Invest. 2008;31(7):653–5.
27. Gazi E, Gencer M, Hanci V, Temiz A, Altun B, Güngör ANÇ, et al. Polikistik over sendromu olan genç kadi{dotless}nlarda QT dispersiyonu ile gonadal hormonlar ve insulin arasi{dotless}ndaki ilişki: Gözlemsel bir çali{dotless}şma. Anadolu Kardiyol Derg. 2013;13(8):772–7.
28. Pecori Giraldi F, Toja PM, Michailidis G, Metinidou A, De Martin M, Scacchi M, et al. High prevalence of prolonged qt interval duration in male patients with Cushing’s disease. Exp Clin Endocrinol Diabetes. 2011;119(4):221–4.
29. Kirilmaz A, Bolu E, Kilicaslan F, Erinc K, Uzun M, Isik E, et al. Comparison of electrocardiographic repolarization patterns between hypogonad males and normal subjects. Ann Noninvasive Electrocardiol. 2003;8(4):284–8.
30. La Fountaine MF, Wecht JM, Cirnigliaro CM, Kirshblum SC, Spungen AM, Bauman WA. Testosterone replacement therapy improves QTaVI in hypogonadal men with spinal cord injury. Neuroendocrinology. 2013;97(4):341–6.
31. Lubart E, Yarovoy A, Gal G, Krakover R, Leibovitz A. QT interval length in elderly prostatic cancer patients on anti-testosterone treatment. Isr Med Assoc J. 2015;17(6):356–8.
32. Olsson H, Petri N, Erichsen L, Malmberg A, Grundemar L. Effect of Degarelix, a Gonadotropin-Releasing Hormone Receptor Antagonist for the Treatment of Prostate Cancer, on Cardiac Repolarisation in a Randomised, Placebo and Active Comparator Controlled Thorough QT/QTc Trial in Healthy Men. Clin Drug Investig. 2017;37(9):873–9.
33. Zhao J, Jiang C, Lam TH, Liu B, Cheng KK, Xu L, et al. Genetically predicted testosterone and electrocardiographic QT interval duration in Chinese: A Mendelian randomization analysis in the Guangzhou Biobank Cohort Study. Int J Epidemiol. 2015;44(2):613–20.
34. Gagliano-Juca T, Betulçli T, Pencina KM, Li Z, Tapper J, Huang G, et al. Effects of testosterone replacement on electrocardiographic parameters in men: Findings from two randomized trials. J Clin Endocrinol Metab. 2017;102(5):1478–85.
35. Gagliano-Jucá T, Travison TG, Kantoff PW, Nguyen PL, Taplin ME, Kibel AS, et al. Androgen deprivation therapy is associated with prolongation of QTc interval inmen with prostate cancer. J Endocr Soc. 2018;2(5):485–96.
36. Huo J, Wei F, Cai C, Lyn-Cook B, Pang L. Sex-Related Differences in Drug-Induced QT Prolongation and Torsades de Pointes: A New Model System with Human iPSC-CMs. Toxicol Sci. 2019;167(2):360–74.
37. La Fountaine MF, Wecht JM, Cirnigliaro CM, Kirshblum SC, Spungen AM, Bauman WA. QT/RR coherence is associated with testosterone levels in men with chronic spinal cord injury. Neuroendocrinology. 2011;93(3):174–80.
38. Piccirillo G, Moscucci F, Pofi R, D’Alessandro G, Minnetti M, Isidori AM, et al. Changes in left ventricular repolarization after short-term testosterone replacement therapy in hypogonadal males. J Endocrinol Invest [Internet]. 2019;42(9):1051–65. Available from: https://doi.org/10.1007/s40618-019-01026-5
39. Salem JE, Waintraub X, Courtillot C, Shaffer CM, Gandjbakhch E, Maupain C, et al. Hypogonadism as a reversible cause of torsades de pointes in men. Circulation. 2018;138(1):110–3.
40. Salem JE, Yang T, Moslehi JJ, Waintraub X, Gandjbakhch E, Bachelot A, et al. Androgenic effects on ventricular repolarization a translational study from the international pharmacovigilance database to iPSC-cardiomyocytes. Circulation. 2019;140(13):1070–80.
41. Vicente J, Johannesen L, Galeotti L, Strauss DG. Mechanisms of sex and age differences in ventricular repolarization in humans. Am Heart J [Internet]. 2014;168(5):749-756.e3. Available from: http://dx.doi.org/10.1016/j.ahj.2014.07.010
42. Wu ZY, Chen K, Haendler B, McDonald T V., Bian JS. Stimulation of N-terminal truncated isoform of androgen receptor stabilizes human ether-á-go-go-related gene-encoded potassium channel protein via activation of extracellular signal regulated kinase 1/2. Endocrinology. 2008;149(10):5061–9.
43. Valverde ER, Biagetti MO, Bertran GR, Arini PD, Bidoggia H, Quinteiro RA. Developmental changes of cardiac repolarization in rabbits: Implications for the role of sex hormones. Cardiovasc Res. 2003;57(3):625–31.
44. Liu XK, Katchman A, Whitfield BH, Wan G, Janowski EM, Woosley RL, et al. In vivo androgen treatment shortens the QT interval and increases the densities of inward and delayed rectifier potassium currents in orchiectomized male rabbits. Cardiovasc Res. 2003;57(1):28–36.
45. Alexandre J, Milliez P, Rouet R, Manrique A, Allouche S, Piccirillo G, et al. Aldosterone and testosterone: Two steroid hormones structurally related but with opposite electrophysiological properties during myocardial ischemia-reperfusion. Fundam Clin Pharmacol. 2015;29(4):341–51.
46. Lujan HL, Kramer VJ, Dicarlo SE. Sex influences the susceptibility to reperfusion-induced sustained ventricular tachycardia and β-adrenergic receptor blockade in conscious rats. Am J Physiol - Hear Circ Physiol. 2007;293(5).
47. Masuda K, Takanari H, Morishima M, Ma FF, Wang Y, Takahashi N, et al. Testosterone-mediated upregulation of delayed rectifier potassium channel in cardiomyocytes causes abbreviation of QT intervals in rats. J Physiol Sci [Internet]. 2018;68(6):759–67. Available from: https://doi.org/10.1007/s12576-017-0590-4
48. Brouillette J, Rivard K, Lizotte E, Fiset C. Sex and strain differences in adult mouse cardiac repolarization: Importance of androgens. Cardiovasc Res. 2005;65(1):148–57.
49. Brouillette J, Trépanier-Boulay V, Fiset C. Effect of androgen deficiency on mouse ventricular repolarization. J Physiol. 2003;546(2):403–13.
50. Crump SM, Hu Z, Kant R, Levy DI, Goldstein SAN, Abbott GW. Kcne4 deletion sex- and age-specifically impairs cardiac repolarization in mice. FASEB J. 2016;30(1):360–9.
51. Hu Z, Wei W, Zhou L, Chen M, Abbott GW. Kcne4 deletion sex-specifically predisposes to cardiac arrhythmia via testosterone-dependent impairment of RISK/SAFE pathway induction in aged mice. Sci Rep. 2018;8(1):1–14.
52. Sun YL, Li PH, Shi L, Su WZ, Li DS, Xue GL, et al. Valsartan reduced the vulnerability to atrial fibrillation by preventing action potential prolongation and conduction slowing in castrated male mice. J Cardiovasc Electrophysiol. 2018;29(10):1436–43.
53. Tsai WC, Lu YY, Chen YC, Chang CJ, Kao YH, Lin YK, et al. Ablation of androgen receptor gene triggers right ventricular outflow tract ventricular tachycardia. Int J Cardiol [Internet]. 2015;189(1):172–81. Available from: http://dx.doi.org/10.1016/j.ijcard.2015.04.080
54. Tsai WC, Yang LY, Chen YC, Kao YH, Lin YK, Chen SA, et al. Ablation of the androgen receptor gene modulates atrial electrophysiology and arrhythmogenesis with calcium protein dysregulation. Endocrinology. 2013;154(8):2833–42.
55. Zhang Y, Wang HM, Wang YZ, Zhang YY, Jin XX, Zhao Y, et al. Increment of late sodium currents in the left atrial myocytes and its potential contribution to increased susceptibility of atrial fibrillation in castrated male mice. Hear Rhythm [Internet]. 2017;14(7):1073–80. Available from: http://dx.doi.org/10.1016/j.hrthm.2017.01.046
56. Drici MD, Burklow TR, Haridasse V, Glazer RI, Woosley RL. Sex hormones prolong the QT interval and downregulate potassium channel expression in the rabbit heart. Circulation. 1996;94(6):1471–4.
57. Lang CN, Menza M, Jochem S, Franke G, Perez Feliz S, Brunner M, et al. Electro-mechanical dysfunction in long QT syndrome: Role for arrhythmogenic risk prediction and modulation by sex and sex hormones. Prog Biophys Mol Biol [Internet]. 2016;120(1–3):255–69. Available from: http://dx.doi.org/10.1016/j.pbiomolbio.2015.12.010
58. Pham T V., Robinson RB, Danilo P, Rosen MR. Effects of gonadal steroids on gender-related differences in transmural dispersion of L-type calcium current. Cardiovasc Res. 2002;53(3):752–62.
59. Pham T V., Sosunov EA, Gainullin RZ, Danilo P, Rosen MR. Impact of sex and gonadal steroids on prolongation of ventricular repolarization and arrhythmias induced by Ik-blocking drugs. Circulation. 2001;103(17):2207–12.
60. Pham T V., Sosunov EA, Anyukhovsky EP, Danilo P, Rosen MR. Testosterone diminishes the proarrhythmic effects of dofetilide in normal female rabbits. Circulation. 2002;106(16):2132–6.
61. Argenziano M, Tiscornia G, Moretta R, Casal L, Potilinski C, Amorena C, et al. Arrhythmogenic effect of androgens on the rat heart. J Physiol Sci. 2017;67(1):217–25.
62. Ayaz M, Akand M, Kucukbagriacik Y, Dursunoglu D. The effects of estradiol on cardiac muscle electrophysiology in orchiectomized rat model: A new insight to side effects caused by castration. Eur Rev Med Pharmacol Sci. 2015;19(15):2866–74.
63. Eleawa SM, Sakr HF, Hussein AM, Assiri AS, Bayoumy NMK, Alkhateeb M. Effect of testosterone replacement therapy on cardiac performance and oxidative stress in orchidectomized rats. Acta Physiol. 2013;209(2):136–47.
64. Shuba YM, Degtiar VE, Osipenko VN, Naidenov VG, Woosley RL. Testosterone-mediated modulation of HERG blockade by proarrhythmic agents. Biochem Pharmacol. 2001;62(1):41–9.
65. Barajas-Martinez H, Haufe V, Chamberland C, Roy MJB, Fecteau MH, Cordeiro JM, et al. Larger dispersion of INa in female dog ventricle as a mechanism for gender-specific incidence of cardiac arrhythmias. Cardiovasc Res. 2009;81(1):82–9.
66. Fülöp L, Bányász T, Szabó G, Tóth IB, Bíró T, Lôrincz I, et al. Effects of sex hormones on ECG parameters and expression of cardiac ion channels in dogs. Acta Physiol. 2006;188(3–4):163–71.
67. Bai CX, Kurokawa J, Tamagawa M, Nakaya H, Furukawa T. Nontranscriptional regulation of cardiac repolarization currents by testosterone. Circulation. 2005;112(12):1701–10.
68. James AF, Arberry LA, Hancox JC. Gender-related differences in venticular myocyte repolarization in the guinea pig. Basic Res Cardiol. 2004;99(3):183–92.
69. Yang PC, Kurokawa J, Furukawa T, Clancy CE. Acute effects of sex steroid hormones on susceptibility to cardiac arrhythmias: A simulation study. PLoS Comput Biol. 2010;6(1).
70. Raghu KG, Singh R, Prathapan A, Yadav GK. Modulation of haloperidol induced electrophysiological alterations on cardiac action potential by various risk factors and gender difference. Chem Biol Interact. 2009;180(3):454–9.
71. Argenziano M, Tiscornia G, Moretta R, Amorena CE, Gras EG. Control hormonal de las corrientes de la fase 1 del potencial de acción cardíaco en el síndrome de Brugada. Rev Argent Cardiol. 2014;82(4):292–7.
72. Muensterman ET, Jaynes HA, Sowinski KM, Overholser BR, Shen C, Kovacs RJ, et al. Effect of transdermal testosterone and oral progesterone on drug-induced QT interval lengthening in older men a randomized, double-blind, placebo-controlled crossover-design study. Circulation. 2019;140(13):1127–9.
73. Tsai WC, Lee TI, Chen YC, Kao YH, Lu YY, Lin YK, et al. Testosterone replacement increases aged pulmonary vein and left atrium arrhythmogenesis with enhanced adrenergic activity. Int J Cardiol [Internet]. 2014;176(1):110–8. Available from: http://dx.doi.org/10.1016/j.ijcard.2014.06.054
74. Van Noord C, Eijgelsheim M, Stricker BHC. Drug- and non-drug-associated QT interval prolongation. Br J Clin Pharmacol. 2010;70(1):16–23.
75. College of Physicians and Surgeons of British Columbia. Drug Associated with QT Interval Prolongation. 2003; Available from: https://www.cpsbc.ca/files/pdf/Methadone-Drugs-QT-Interval-Prolongation.pdf
76. Nachimuthu S, Assar MD, Schussler JM. Drug-induced QT interval prolongation: Mechanisms and clinical management. Ther Adv Drug Saf. 2012;3(5):241–53.
77. Cheng J. Evidences of the gender-related differences in cardiac repolarization and the underlying mechanisms in different animal species and human. Fundam Clin Pharmacol. 2006;20(1):1–8.
78. Drug F, Bulletin T. QT interval and drug therapy. BMJ. 2016;353(June):1–5.
79. Lapointe NMA, Kramer JM, Califf RM. About the QT Interval. 2003;289(16).